Skip to main content
Premium Trial:

Request an Annual Quote

Lynx, Millennium to Use MPSS for Gene-Expression Research

NEW YORK, May 15 - Lynx Therapeutics will use its Massively Parallel Signature Sequencing technology to help Millennium Pharmaceuticals study gene expression in certain blood cell populations, the companies said today.

 

Terms of the agreement call for Lynx to apply the MPSS technology in two separate studies: First the MPSS platform will be used to identify cell-specific gene markers for an undisclosed blood cell type.

In the second study, Lynx will use the platform to evaluate gene-expression patterns from RNA in peripheral blood monocytes following treatments with certain undisclosed compounds.

 

Click here for more informatin.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.